Following the successful completion of the NHS national pilot in April 2025, the highly anticipated first results assessing CYP2C19 genetic testing to guide clopidogrel use in ischaemic stroke and TIA ...

The optimism is not unfounded. In specific, well-defined clinical scenarios, polygenic scores are beginning to demonstrate some tangible utility. For cardiovascular disease, MI-GENES, a 10-year follow ...

The UK government has launched a new alliance to sequence the genomes of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. Backed by a £20 million investment, the COVID-19 Genomics ...

These plans have been a long time in the making. The intention to produce a strategy ‘to ensure the UK is able to offer a predictive, preventative and personalised health and care service for people ...

The rapid development, approval and roll out of multiple vaccines against SARS-CoV-2, the virus that causes COVID-19, is an impressive achievement for science and healthcare. The virus genome was ...

Widely regarded as a founder of cell free DNA (cfDNA) technology, Professor Dennis Lo is now pioneering investigation into the emerging science of fragmentomics. If you were at were at our recent ...

Cost-utility studies provide critical information for the costs and benefits of using any new test, typically building on existing public health and screening programmes, within a defined population.

Until the coronavirus pandemic took hold, it seemed that at least every other headline about healthcare innovations was related to machine learning or other forms of artificial intelligence (AI) – ...

The European Health Data Space Regulation has arrived but will its mandatory sharing requirement be its tour de force or Achilles’ heel? The Regulation amounts to an ambitious and laudable step ...

Not all patients are benefitting equally from advances in genomic research. Research databases and biobanks underpinning genetic tests and tools are full of data from populations labelled as “European ...

A recent consultation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) indicates a welcome new direction for public and patient involvement (PPI). The MHRA proposed new five-year ...

The Wellcome Trust recently announced that they are funding a research programme to investigate synthetic human genomes, and Laura Blackburn, PHG Foundation’s Head of Science, had the opportunity to ...